Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04646889 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment
A Phase 1 study of Renal Impairment, sponsored by Arthrosi Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 4
- Study locations
NCT04646889: Completed Phase 1 study of Renal Impairment, sponsored by Arthrosi Therapeutics.
NCT04646889 is a Phase 1 study of Renal Impairment that has completed, run by Arthrosi Therapeutics. The registered enrollment target is 46 participants, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (39% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04646889, a Phase 1 study of Renal Impairment, has completed, sponsored by Arthrosi Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.
Conditions Studied
Interventions
- DRUG AR882 Single Dose
- DRUG AR882 Multiple Dose
Study Locations (4)
Other
- Arthrosi Investigative Site - Auckland
- Arthrosi Investigative Site - Christchurch
Florida
- Arthrosi Investigative Site - Orlando
Texas
- Arthrosi Investigative Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-01-14 |
| Est. Completion | 2022-06-27 |
| Phase | Phase 1 |
What the finished NCT04646889 record still lists
NCT04646889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (39% higher).
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 2 interventions - of which AR882 Single Dose is the first listed.
NCT04646889 reports a single indexed study location in Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04646889 about?
NCT04646889 is a clinical study titled "Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment". This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.
What is the current status of trial NCT04646889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-01-14. Estimated completion is 2022-06-27.
What conditions does trial NCT04646889 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT04646889?
The interventions under investigation include: AR882 Single Dose (DRUG), AR882 Multiple Dose (DRUG).
Who is sponsoring clinical trial NCT04646889?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04646889 being conducted?
This trial has 4 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04646889's enrollment target sits among peer trials
46 7th of 32 higher than 26 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI